Methods for treating polycystic kidney disease and polycystic liver disease
The present invention provides compounds of Formula (I) or (II), which are thought to be able to inhibit mTOR (mammalian target of rapamycin) signaling pathway, induce UPR (unfolded protein response), and/or perturb mitochondrial function of a cyst cell (e.g., a cyst cell causing polycystic kidney disease (PKD, e.g., autosomal dominant PKD (ADPKD) or autosomal recessive PKD (ARPKD)) or polycystic liver disease (PLD, e.g., autosomal dominant PLD (ADPLD) or autosomal recessive PLD (ARPLD)). The invention also provides pharmaceutical compositions, kits, and methods involving the compounds described herein for use in treating PKD or PLD, inhibiting the growth of a cyst cell, and/or killing a cyst cell.
1. A method of treating polycystic kidney disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound, wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of said compound.
2. The method of claim 1 , wherein the polycystic kidney disease is autosomal dominant polycystic kidney disease.
3. The method of claim 1 , wherein the polycystic kidney disease is autosomal recessive polycystic kidney disease.
4. A method of treating polycystic liver disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound, wherein the compound is of formula:
or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of said compound.
5. The method of claim 4 , wherein the polycystic liver disease is autosomal dominant polycystic liver disease.
6. The method of claim 4 , wherein the polycystic liver disease is autosomal recessive polycystic liver disease.